Literature DB >> 26650611

Angiogenic and Immunomodulatory Properties of Endothelial and Mesenchymal Stem Cells.

Sushma Bartaula-Brevik1, Torbjorn O Pedersen1, Anna Finne-Wistrand2, Anne Isine Bolstad1, Kamal Mustafa1.   

Abstract

It has been suggested that the effect of implanted cells on the local environment is important when selecting the appropriate cell type for tissue regeneration. Our aim was to compare the local tissue response to implanted human mesenchymal stem cells (MSC) and human umbilical vein endothelial cells (EC). MSC and EC were cultured in poly(L-lactide-co-1,5-dioxepan-2-one) scaffolds for 1 week in a bioreactor system, after which they were implanted subcutaneously in NOD/SCID mice. After 3 weeks, scaffolds were retrieved, and the mRNA expression of selected genes involved in hypoxia and inflammation was examined by real-time reverse transcription polymerase chain reaction and correlated with immunofluorescent staining for corresponding proteins. The Toll-like receptor signaling pathway was examined by superarray hybridization. The expression of 53 angiogenesis-related proteins was investigated by a proteome profiler angiogenesis antibody array kit. Vascularization was quantified using immunohistochemistry for CD31. The expression of hypoxia-inducible factors and biomarkers for angiogenesis was more strongly upregulated in response to implanted EC than to MSC, suggesting a higher sensitivity to low oxygen tension among EC. Hypoxic signaling was increased after implantation of EC compared with MSC, leading to a prolonged acute inflammatory phase that promoted ingrowth of vascular cells and establishment of the circulation. Inflammatory cytokines were also differently expressed at the gene and protein levels in the two experimental groups, resulting in altered recruitment of acute and chronic inflammatory cells. The end result of these differences was increased vessel formation within the constructs in the EC group.

Entities:  

Mesh:

Year:  2016        PMID: 26650611      PMCID: PMC4779276          DOI: 10.1089/ten.TEA.2015.0316

Source DB:  PubMed          Journal:  Tissue Eng Part A        ISSN: 1937-3341            Impact factor:   3.845


  40 in total

Review 1.  Neutrophils: key mediators of tumour angiogenesis.

Authors:  Simon Tazzyman; Claire E Lewis; Craig Murdoch
Journal:  Int J Exp Pathol       Date:  2009-06       Impact factor: 1.925

Review 2.  The role of nitric oxide (NO) in stability regulation of hypoxia inducible factor-1alpha (HIF-1alpha).

Authors:  Bernhard Brüne; Jie Zhou
Journal:  Curr Med Chem       Date:  2003-05       Impact factor: 4.530

3.  Pigment epithelium-derived factor: a potent inhibitor of angiogenesis.

Authors:  D W Dawson; O V Volpert; P Gillis; S E Crawford; H Xu; W Benedict; N P Bouck
Journal:  Science       Date:  1999-07-09       Impact factor: 47.728

4.  Effect of endothelial cells on bone regeneration using poly(L-lactide-co-1,5-dioxepan-2-one) scaffolds.

Authors:  Zhe Xing; Ying Xue; Staffan Dånmark; Kerstin Schander; Siren Ostvold; Kristina Arvidson; Sølve Hellem; Anna Finne-Wistrand; Ann-Christine Albertsson; Kamal Mustafa
Journal:  J Biomed Mater Res A       Date:  2010-12-06       Impact factor: 4.396

5.  Thrombin induces endothelial type II activation in vitro: IL-1 and TNF-alpha-independent IL-8 secretion and E-selectin expression.

Authors:  G Kaplanski; M Fabrigoule; V Boulay; C A Dinarello; P Bongrand; S Kaplanski; C Farnarier
Journal:  J Immunol       Date:  1997-06-01       Impact factor: 5.422

6.  CCN3 (NOV) is a novel angiogenic regulator of the CCN protein family.

Authors:  Cristiane G Lin; Shr-Jeng Leu; Ningyu Chen; Christopher M Tebeau; Shao-Xia Lin; Cho-Yau Yeung; Lester F Lau
Journal:  J Biol Chem       Date:  2003-04-13       Impact factor: 5.157

Review 7.  Modulation of the inflammatory response for enhanced bone tissue regeneration.

Authors:  Paschalia M Mountziaris; Antonios G Mikos
Journal:  Tissue Eng Part B Rev       Date:  2008-06       Impact factor: 6.389

8.  CXCL17 expression by tumor cells recruits CD11b+Gr1 high F4/80- cells and promotes tumor progression.

Authors:  Aya Matsui; Hideaki Yokoo; Yoichi Negishi; Yoko Endo-Takahashi; Nicole A L Chun; Ichiro Kadouchi; Ryo Suzuki; Kazuo Maruyama; Yukihiko Aramaki; Kentaro Semba; Eiji Kobayashi; Masafumi Takahashi; Takashi Murakami
Journal:  PLoS One       Date:  2012-08-29       Impact factor: 3.240

9.  Endothelial microvascular networks affect gene-expression profiles and osteogenic potential of tissue-engineered constructs.

Authors:  Torbjorn O Pedersen; Anna L Blois; Zhe Xing; Ying Xue; Yang Sun; Anna Finne-Wistrand; Lars A Akslen; James B Lorens; Knut N Leknes; Inge Fristad; Kamal Mustafa
Journal:  Stem Cell Res Ther       Date:  2013-05-17       Impact factor: 6.832

10.  A hypoxia-responsive element mediates a novel pathway of activation of the inducible nitric oxide synthase promoter.

Authors:  G Melillo; T Musso; A Sica; L S Taylor; G W Cox; L Varesio
Journal:  J Exp Med       Date:  1995-12-01       Impact factor: 14.307

View more
  6 in total

1.  A Prevascularized Polyurethane-Reinforced Fibrin Patch Improves Regenerative Remodeling in a Rat Right Ventricle Replacement Model.

Authors:  Ze-Wei Tao; Dillon K Jarrell; Andrew Robinson; Elizabeth M Cosgriff-Hernandez; Jeffrey G Jacot
Journal:  Adv Healthc Mater       Date:  2021-10-08       Impact factor: 9.933

2.  SMAD-specific E3 ubiquitin ligase 2 promotes angiogenesis by facilitating PTX3 degradation in MSCs from patients with ankylosing spondylitis.

Authors:  Mengjun Ma; Wen Yang; Zhaopeng Cai; Peng Wang; Hongyu Li; Rujia Mi; Yuhang Jiang; Zhongyu Xie; Pengfei Sui; Yanfeng Wu; Huiyong Shen
Journal:  Stem Cells       Date:  2021-02-06       Impact factor: 6.277

Review 3.  Immunomodulators and microRNAs as neurorestorative therapy for ischemic stroke.

Authors:  Bridget Martinez; Philip V Peplow
Journal:  Neural Regen Res       Date:  2017-06       Impact factor: 5.135

Review 4.  Principal Criteria for Evaluating the Quality, Safety and Efficacy of hMSC-Based Products in Clinical Practice: Current Approaches and Challenges.

Authors:  Juan Antonio Guadix; Javier López-Beas; Beatriz Clares; José Luis Soriano-Ruiz; José Luis Zugaza; Patricia Gálvez-Martín
Journal:  Pharmaceutics       Date:  2019-10-24       Impact factor: 6.321

Review 5.  Mesenchymal stromal cell therapies: immunomodulatory properties and clinical progress.

Authors:  Xiaomo Wu; Ju Jiang; Zhongkai Gu; Jinyan Zhang; Yang Chen; Xiaolong Liu
Journal:  Stem Cell Res Ther       Date:  2020-08-08       Impact factor: 6.832

Review 6.  Application of vascular endothelial cells in stem cell medicine.

Authors:  Qing-Qing Liang; Lei Liu
Journal:  World J Clin Cases       Date:  2021-12-16       Impact factor: 1.337

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.